CMS backs off Part D revision

Share this article:

The proposal to reduce the number of drugs Medicare Part D has to cover among certain classes is dead. CMS Administrator Marilyn Tavenner sent a note to Rep. Henry Waxman (D-CA) Monday saying that her agency would no longer pursue the change based on stakeholder feedback, or, as Politico described it, “withering criticism from the industry, patient advocacy groups and lawmakers.”

Waxman is the ranking member of the House Energy and Commerce Committee.

CMS issued the proposal in January. The aim was to limit the options in three drug classes, for cost control reasons, but the financial argument was as much an industry irritant as it was a political one.

Modern Healthcare described Monday's move as “political cover ahead of the mid-term elections,” and noted that the overall draft, which included this Medicare Part D drug proposal was “universally panned.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.